We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current LGND market cap is 1.28B. The company's latest EPS is USD 2.9457 and P/E is 24.59.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 66.09M | 27.05M | 43.98M | 26.37M | 34.99M |
Operating Income | 636k | 12.18M | 14.21M | -1.98M | 3.08M |
Net Income | 404k | -17.49M | 41.95M | 2.29M | -10.27M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 120.28M | 186.42M | 314.73M | 196.25M | 131.31M |
Operating Income | -5.72M | 8.73M | 78.9M | 3.04M | 9.82M |
Net Income | 629.3M | -2.99M | 57.14M | -33.36M | 52.15M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 1.05B | 762.67M | 811.08M | 758.11M | 769.23M |
Total Liabilities | 234.31M | 165.18M | 164.76M | 93.21M | 101.33M |
Total Equity | 816.3M | 597.49M | 646.32M | 664.89M | 667.9M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 1.49B | 1.36B | 1.3B | 762.67M | 787.22M |
Total Liabilities | 727.68M | 652.76M | 476.43M | 165.18M | 86.3M |
Total Equity | 767.23M | 709.53M | 821.16M | 597.49M | 700.91M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 84.38M | 137.85M | 33.95M | 33.87M | 41.51M |
Investing | 170.91M | 163.62M | 10.55M | 18.11M | -1.4M |
Financing | -270.69M | -275.99M | -775k | -68.53M | -65.26M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -29.34M | 54.59M | 78.8M | 137.85M | 49.58M |
Investing | 466.92M | 231.65M | 30.52M | 163.62M | -11.68M |
Financing | -485.17M | -310.55M | -137.76M | -275.99M | -59.95M |
Market Cap | 1.28B |
Price to Earnings Ratio | 24.59 |
Price to Sales Ratio | 9.77 |
Price to Cash Ratio | 55.87 |
Price to Book Ratio | 1.83 |
Dividend Yield | - |
Shares Outstanding | 17.71M |
Average Volume (1 week) | 126.09k |
Average Volume (1 Month) | 159.96k |
52 Week Change | -5.65% |
52 Week High | 94.57 |
52 Week Low | 49.24 |
Spread (Intraday) | 7.51 (10.01%) |
Company Name | Ligand Pharmaceuticals Incorporated |
Address |
251 little falls drive wilmington, delaware 19808 |
Website | https://www.ligand.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions